NEW YORK (GenomeWeb) – The Epilepsy Foundation has teamed with Pfizer and Intellimedix to create a drug discovery platform targeted toward patients with genetic forms of epilepsy, the foundation said today.
The partners hope the drug screening platform will be used to create individualized treatments for people with Dravet Syndrome, a severe form of genetic epilepsy, and for other types of this disease for which there are only limited treatment options.
Atlanta-based Intellimedix uses next-generation sequencing, predictive analytics, and in vitro animal models to discover, develop, validate, and repurpose drugs and diagnostics for epilepsy and other neurological disorders.
"This collaboration has the potential to benefit all individuals and families living with epilepsy, especially the one-third of people with epilepsy who live with uncontrolled seizures despite all currently available therapies," Epilepsy Foundation President and CEO Philip Gattone said in a statement.